DICLOXACILLIN SODIUM

Post-LOE

dicloxacillin sodium

Molecular Devices

ANDAORALCAPSULE

Approved

Apr 1971

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

4/8 — Partial

DICLOXACILLIN SODIUM (dicloxacillin sodium) by Molecular Devices is clinical pharmacology microbiology mechanism of action penicillinase-resistant penicillins exert a bactericidal action against penicillin-susceptible microorganisms during the state of active multiplication. Approved for the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. First approved in 1971.

Drug data last refreshed 18h ago

$0.0BPart D

Mechanism of Action

CLINICAL PHARMACOLOGY Microbiology Mechanism of Action Penicillinase-resistant penicillins exert a bactericidal action against penicillin-susceptible microorganisms during the state of active multiplication. All penicillins inhibit the biosynthesis of the bacterial cell wall. Antibacterial Activity…

Indications (1)

Worked on DICLOXACILLIN SODIUM at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.